• כרטיס רופא והטבות
  • אתרי הר"י
  • צרו קשר
  • פעולות מהירות
  • עברית (HE)
  • מה תרצו למצוא?

        תוצאת חיפוש

        אוגוסט 2001

        טל בוניאל ופנחס דנון
        עמ'

        טל בוניאל (1), פנחס דנון (2)

         

        שירותי הרוקחות (1) והחטיבה לפסיכיאטריה (2), מרכז רפואי שיבא, תל השומר

         

        העלייה בשיעור הטיפול בצמחי מרפא ושיווקם הנרחב בבתי מרקחת ובבתי טבע, לעתים ללא כל פיקוח או ייעוץ מקצועי, מחייבת את אנשי המקצוע לנקוט בגישה חדשה. לצמחי מרפא רבים יש השפעה על מצב הרוח, החשיבה וההתנהגות, ולכן רבים מהלוקים בתסמינים נפשיים שונים פונים לרפואה הטבעית ולקבלת טיפול.

        במאמר זה נביא מספר דוגמאות לצמחי מרפא ששיווקם נפוץ, הניתנים כטיפול בתסמינים פסיכיאטריים, ונדון ביעילותם ובבטיחות נטילתם.

        יולי 2001

        רפאל נגלר, יפעת קליין ואברהם רזניק
        עמ'

        The Interaction Between Saliva and Cigarette Smoke and its Devastating Biological Effects as Related to Oral Cancer

         

        Rafael M. Nagler, Ifat Klein, Abraham Z. Reznick

         

        Department of Oral & Maxillofacial Surgery, Salivary Clinic and Oral Biochemistry Laboratory and Department of Anatomy and Cell Biology, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel

         

        Saliva is the first body fluid to confront inhaled cigarette smoke (CS) which is injurious to the oral cavity and is associated with several oral diseases and cancer. We have recently demonstrated in an In vitro model that an exposure of saliva to nine `puffs' of CS induced a distinct increase in protein carbonyls. This elevation of protein carbonyls caused by CS may be the result of aldehydes presented in the CS reacting with sulphydryl (-SH) groups of the proteins. Moreover, following the exposure to CS, the activities of several salivary enzymes amylase, lactate dehydrogenase (LDH) and acid phosphatase (ACP) were found to be significantly reduced by 83%, 57% and 77%, respectively. However, CS had no effect on the activities of aspartate aminotransferase and alkaline phosphatase. In the current study we found that CS also reduced salivary peroxidase activity by no less than 80% which may be of a great importance to the clinical set up as peroxidase is considered a pivotal enzyme of the the salivary protecting system. Furthermore, in contrast to LDH findings in saliva, the LDH activity in plasma was not reduced following its exposure to CS.

        Conclusion: Hence, we concluded that the loss of salivary enzyme activities may be due to various agents in the CS that affect the enzyme via different mechanisms.

        אפריל 2001

        דניאל אלבירט, מרב פרנקל-רובין, דויד ארגז, זאב שטגר
        עמ'

        דניאל אלבירט, מרב פרנקל-רובין, דויד ארגז, זאב שטגר

         

        המח' לרפואה פנימית ב', המרכז הרפואי קפלן, רחובות, מסונף לפקולטה של האוניברסיטה העברית והדסה, ירושלים

         

        בעבודה הקלינית עומדים הרופאים, פעמים רבות, בפני התלבטויות איבחוניות וטיפוליות של חולים במצב קשה, לגביהם האבחנה אינה. וכך, קיימים מצבים בהם לא ניתן לקבוע בוודאות, האם הבסיס למחלה או זיהומי-חיידקי, מחלה זיהומית אחרת (לדוגמה, מחלה נגיפית) או מחלה דלקתית שאינה זיהומית. לדוגמה, בחולה הלוקה במחלה אוטואימונית, לא תמיד ניתן לקבוע האם האבחנה היא התפרצות של המחלה הבסיסית המצריכה טיפול בסטרואידים או בתרופות מדכאות-חיסון, או שהחולה לוקה בזיהום חיידקי חד או באלח-דם המצריכים גישה טיפולית שונה לגמרי (אנטיביוטיקה). באופן דומה ניתן לתאר מצבים נוספים, כמו האבחנה בין דחיית שתל לבין זיהום מישני לצורך הערכת התגובה הדלקתית בחולה שמצבו קשה מבוססים על הערכה קלינית סובייקטיבית ובדיקות דם כגון נוסחת-דם. שקיעת-דם ורמות CRP (C-reactive protein) או ציטוקינים אחרים בנסיוב כדוגמת IL-6 – כולם מדדים בעלי סגוליות נמוכה יחסית. כמו כן, תרביות (דם,שתן, כיח וכד') המהוות מרכיב חיוני לאיבחון זיהומים, מצריכות זמן (בדרך כלל ימים) עד לקבלת תוצאה. בנוסף, תרביות עקרות אינן שוללות תהליך זיהומי (טיפול חלקי באנטיביוטיקה, חיידקים מיוחדים וכד'). מכאן, שקיים צורך במדד מעבדתי זמין מהיר וטוב יותר, שיאפשר איבחון מהיר וגישה טיפולית נכונה.

        ינואר 2001

        רפאל נגלר ואברהם זאב רזניק
        עמ'

        Antioxidant Profile of Human Saliva and its Biological Significance

         

        R. M. Nagler, A. Z. Reznick

         

        Dept. of Oral and Maxillofacial Surgery, Salivary Clinic and Oral Biochemistry Laboratory; Rambam Medical Center and Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa

         

        Saliva is the first biological medium to come in contact with materials entering the body through the oral cavity. These materials are contained in food and drink (or inhaled as volatile ingredients). Accordingly, saliva contains various defense mechanisms which have been thoroughly investigated. They include immunological and enzymatic systems aimed at pathological microorganisms. Saliva also can protect the mucosa against mechanical insults and when required, promote its healing via agents such as the epidermal growth factor.

        Another defense mechanism in saliva which has been gaining increased attention and seems to be of paramount importance is its antioxidant system. We discuss both the molecular and enzymatic components of the salivary antioxidant system in respect to mixed, parotid, submandibular and sublingual saliva and under various physiological conditions of secretion.

         
         

        מאי 2000

        סימה לבני, אריאל המרמן, שגב שני ויהושע שמר
        עמ'

        Israel Hospital Pharmaceutical Services: A National Survey 


        S. Livny, A. Hammerman, S. Shani, J. Shemer

         

        Hiliel Yaffe Medical Center, Hadera; Israel Center for Technology Assessment in Health Care; Gertner Institute, Tel HaShomer; Dept. of Internal Medicine, Sheba Medical Center, Tel HaShomer; and Sackler School of Medicine, Tel Aviv University

         

        Results of a 1996 survey of hospital pharmaceutical services in Israel are presented. A questionnaire was mailed to 46 pharmacy directors in Israel hospitals of which a total of 33 were returned (72%).

        The main services provided at hospital pharmacies are production of pharmaceuticals and inventory management. The pharmacy directors estimated that more then half of their pharmacists' time was spent on technical work that did not need their academic, professional knowledge. In Israel general hospitals there are on the average 1.23 full time pharmacist positions per 100 hospital beds and 1.09 positions for other pharmacy employees.

        A similar survey carried out in the United States showed an average of 7.4 pharmacists per 100 hospital beds. Pharmacists there have broad clinical roles which, in general Israeli pharmacists do not have.

        Computer systems are used in our pharmacies mainly for inventory management. About half of the directors did not think that the location, structure and furnishings of their pharmacy were appropriate for its role.

        Under current conditions, Israel hospital pharmacies are not organized to provide pharmaceutical services beyond inventory management and pharmaceutical production. Appropriate budgets and personnel are required to develop clinical pharmacy services at Israel hospitals. This would lead to improved quality of drug treatment and cost-containment and would allow pharmacists to exploit their knowledge, skills and training that under the current system, are only partially utilized.

        אפריל 2000

        ד' ב' גפן, ס' מן וי' כהן
        עמ'

        Etoposide and Cisplatin for Non-Small Cell Lung Cancer 


        David B. Geffen, Sofia Man, Yoram Cohen*

         

        Dept. of Oncology, Soroka-University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba

         

        Etoposide and cisplatin (EP) has been the standard therapy for non-small cell lung cancer (NSCLC) at many cancer centers for over a decade. We analyzed our experience with EP in NSCLC to provide a baseline for comparison with new drugs. From 1986 through 1994, 46 of our patients with NSCLC received EP as first-line chemotherapy. Radiation therapy was administered to 25 of them, including 20 who received it immediately before or concomitantly with chemotherapy. Toxicity was mild and included only 1 episode of neutropenic fever and 1 case of reversible renal failure.

        Overall response was 22%. In 3, response was complete (pathologically documented in 2 of them) and in 7 partial. Median survival in locally advanced (stage III) and metastatic disease (stage IV and recurrent) were 12 months and 7 months, respectively. 2 patients are alive and free of disease more than 6 years after diagnosis.

        Our results are consistent with other published studies of EP in NSCLC. EP provides modest benefit in locally advanced NSCLC, with minimal toxicity.

        Jules E. Harris Chair in Oncology.

        לאוניד אומנסקי, אברהם דורביץ ואבנר סלע
        עמ'

        Alopecia Due to Seroxat 


        Leonid Umansky, Abraham Dorevitch, Avner Sella

         

        Psychiatry Chronic Dept., Eitanim Mental Health Center, Jerusalem

         

        There are 2 stages of alopecia, anagen and telogen effluvium, both of which may be associated with medication- related alopecia. We describe massive hair loss in a 51-year-old woman during treatment with Seroxat (paroxetine), which remitted after it was discontinued. Pathological mechanisms of drug-associated alopecia are complex and have yet to be fully elucidated.

        פברואר 2000

        מאיר מועלם, זהבית טורוק, דני רוזין וברוריה שלמון
        עמ'

        Sclerosing Mesenteritis: An Unusual Cause of Abdominal Pain

         

        Meir Mouallem, Zehavit Turok, Danny Rosin, Bruria Shalmon

         

        Depts. of Medicine E, General Surgery and Transplantation, and of Pathology, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University

         

        Sclerosing mesenteritis (SM) is rare and fewer than 300 cases had been reported up to 1997. We describe a 29-year-old woman who had abdominal pain for 1 year and presented with a palpable abdominal mass. The diagnosis of SM was made only after diagnostic laparoscopy and biopsy of the peritoneum.

        יוני 1999

        ע' ברוק וי' בוינובר
        עמ'

        Rehospitalization of Children

         

        U. Brook, Y. Buyanover

         

        Pediatrics Dept., Wolfson Medical Center, Holon, and Sackler Medical School, Tel Aviv University

         

        The aims of the study were to determine the rate of rehospitalization in 1997 a month after the end of initial hospitalization. 72 of 1174 children (6.1%) were rehospitalized. The mean age was 4.6±3.6 years (range 1 month-16 years). The average duration of the initial hospitalization of the 72 children was 8.3±6.0 (range 1-50) days, but only 3.6 days for all hospitalized children. The duration of the rehospitalization was 4.1±2.1 days (range 1-10 days). the interval between the 2 hospitalizations was 11.1±9.6 days (range 1-30 days). Among the diseases of the rehospitalized children in decreasing order were: respiratory diseases (including ORL) (40.9%), gastrointestinal diseases (27.7%), nervous system diseases, and bacteremia and septicemia (5.6%). Second hospitalizations in connection with these conditions were: gastrointestinal disease (34.7%); respiratory disease (29%); and bacteremia and septicemia (11.1%). Our recommendations are for attending physicians to follow-up regularly and periodically children who suffer from chronic diseases and are prone to develop exacerbations. This should be done in cooperation with hospital specialists so that the cooperation may reduce the rehospitalization of these children.

        ג' איזיקיאל, ש' ולפיש וי' כהן
        עמ'

        Adjuvant Therapy of Large Bowel Carcinoma

         

        G. Ezekiel, S. Walfisch, Y. Cohen*

         

        Dept. of Oncology and Colorectal Unit, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba

         

        The National Institutes of Health (NIH) held a consensus conference which recommended 5-FU and levamisole as adjuvant chemotherapy for colon cancer MAC (Modified Astler Coller) stage C.

        From 1991-1994, 37 such patients diagnosed here were treated with 5-FU (intravenous dose of 450/mg/m²/d for 5 days and from day 29, once a week for 48 weeks) and oral levamisole (50 mg 3 times/d. for 3 days, every 2 weeks for a year), as suggested by NIH guidelines.

         

        16 patients were males and 21 were females, mean age was 62 years and median 64. Cancer locations were: right colon (in 16, 43%), left colon (19, 51%), multiple colon primaries (2, 1%). 25 (68%) had 1-3 positive lymph nodes and 12 (32%) had 4 or more positive lymph nodes.

        Only 20 (54%) finished treatment as prescribed. In the others, 1 or both drugs caused side-effects for which the drugs had to be stopped. 6 patients relapsed while on treatment.

         

        The most common side-effects were diarrhea, stomatitis and bone marrow suppression. 3 were hospitalized due to neutropenic fever. 5-year actuarial survival of all patients was 61%; 5-year relapse-free survival was 61%; 5-year relapse-free survival of right versus left colon was 41% and 82%, respectively (p<0.01). There was no significant difference in 5-year survival of those with 1-3 positive lymph nodes as compared to those with 4 or more (62% and 56%, respectively). 5-year survival in those who finished or did not finish treatment (excluding those who stopped treatment because of progressive disease) was 83% and 70%, respectively (NS).

         

        The 5-year survival of our series was similar to that of patients treated similarly elsewhere. The 5-FU and levamisole treatment was not tolerated well by our study population. It has recently been replaced in our service by a 5-FU and leucovorin regimen given for 6 months.

         

        * Jules E. Harris Chair in Oncology.

        אריאל המרמן, רמונה רותם, נפתלי מידן ואבי פורת
        עמ'

        Impact of Clinical Pharmacist on Drug Therapy in Medical Departments

         

        Ariel Hamerman, Rimona Rotem, Naftali Meidan, Avi Porath

         

        Pharmacy Services, Hospital Management and Medical Dept. F, Soroka University Medical Center, Beer Sheba

         

        Several studies have documented the impact of clinical pharmacy services on patient care and drug costs in hospital wards. However most hospitals in Israel do not provide such services and until recently their benefits in local health care have not been demonstrated. We therefor determined whether the activity of a pharmacist in the medical department of a medical center leads to improved quality of drug utilization and reduced costs.

         

        During the first 3 months of the clinical pharmacist's work all interventions and consultation were documented. The effect of these interventions on drug costs was calculated by the change in drug acquisition costs during the study period compared with those of preceding months, as well as in the other 5 medical departments of the hospital without clinical pharmacy services.

         

        During the study period the pharmacist joined 44 clinical rounds in which he documented 40 consultations in response to physicians' requests for drug information and 42 interventions on his own initiative. The pharmacist's recommendations were accepted in 38 of the 42 cases (90%). In 10 cases the pharmacist's initiative in improving the quality of drug therapy led to an increase in drug acquisition costs. However, the overall drug costs during the study period decreased 12.6%. During the same period drug costs in the other medical departments decreased only 2.2%.

         

        The results of this study conform with those of many other studies that show a beneficial impact of the clinical pharmacist on the quality of drug therapy and on drug costs. They indicate that the clinical pharmacist can play a crucial role in the medical department.

        אפריל 1999

        רפאל נגלר
        עמ'

        Irradiation Injury of the Salivary Glands

         

        R. M. Nagler

         

        Dept. of Oral and Maxillofacial Surgery and Oral Biochemistry Laboratory, Rambam Medical Center and Technion Faculty of Medicine, Haifa

         

        Ionizing irradiation of the salivary glands often leads to severe histological and functional alterations. Such exposure usually occurs during radiotherapy in patients with head and neck malignancy. The consequent xerostomia, often life-long, may result from even relatively low dosage irradiation, and causes a great deal of suffering. We suggest a radiobiological mechanism for this phenomenon which has been studied extensively since first described in 1911. The suggested injurious role of redox active transition metal ions and highly destructive free radicals is discussed in relation to the ultimate radiosensitive cellular target, DNA.

        פברואר 1999

        יאיר סקורניק, סופה ברנדינר, גרא גנדלמן וזאב שטגר
        עמ'

        Cerebellar Infarction: Clinical Presentation, Diagnosis and Treatment

         

        Y. Skurnik, S. Brandiner, G. Gandelman, Z. Shtoeger

         

        Medical Dept., Kaplan Medical Center, Rehovot (Affiliated with Hebrew University-Hadassah Medical School, Jerusalem) and Dept. H, Harzfeld Hospital, Gedera

         

        Cerebellar infarction is relatively infrequent and accounts for about 2% of all strokes. Its clinical presentation and course are variable. It may resemble vestibulitis in mild cases, but the presentation may be more dramatic in other cases. Cerebellar infarction may cause life-threatening complications such as acute hydrocephalus or brain stem compression, resulting from their mass effect in the posterior fossa or extension of the infarct to the brain stem.

        Clinical features alone are insufficient for the diagnosis and for follow-up of patients with cerebellar infarction. However the advent of CT and MRI and their availability enable early diagnosis of cerebellar infarction, and early recognition of the development of acute hydrocephalus or brain stem compression which require surgical decompression. The prognosis of most cases is good when treatment is appropriate.

        ינואר 1999

        זהבי כהן, ניצה נוימן, עדנה קורצברט, ודים קפולר ואברהם מרש
        עמ'

        Diagnostic and Therapeutic Laparoscopy for Non-Palpable Testis

         

        Zahavi Cohen, Niza Newman, Edna Kurzbart, Vadim Kapuller, Abraham J. Mares

         

        Dept. of Pediatric Surgery, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba

         

        From January 1994 to July 1997, 20 boys 1.5-13 years of age underwent laparoscopic examination and treatment for non-palpable testis. In 1 there was bilateral nonpalpable testis. Only 3 had intra-abdominal testes viable for orchiopexy. In 8 atrophic testicles were removed and in 9 laparoscopic examination revealed intra-abdominal blind ending of the spermatic cord and no testicular tissue.

        We conclude that laparoscopy is a useful and safe technique for accurate diagnosis and may avoid additional intervention in treating non-palpable testes. Furthermore, intra-abdominal testes may be managed laparoscopically under the same anesthetic.

        דצמבר 1998

        דורון זמיר, רסמי מג'דלה ופלטיאל וינר
        עמ'

        Normotensive Hydrocephalus Complicating Recurrent E. Coli Meningitis

         

        Doron Zamir, Rasmi Magadle, Paltiel Weiner

         

        Dept. of Medicine A, Hillel Yaffe Medical Center, Hadera

         

        E. coli meningitis is a disease that occurs in predisposed patients, either as a result of trauma or in neonates after neurosurgery. Recurrent E. coli meningitis in an adult without any apparent predisposition is uncommon, and hydrocephalus complicating bacterial meningitis is even more rare. We report a unique case of a 67-year-old alcoholic man who had had 2 consecutive episodes of E. coli meningitis within 2 months. In both episodes there was a favorable response to ceftriaxone. However, normotensive hydrocephalus appeared a few weeks later, with mental and physical deterioration.

        הבהרה משפטית: כל נושא המופיע באתר זה נועד להשכלה בלבד ואין לראות בו ייעוץ רפואי או משפטי. אין הר"י אחראית לתוכן המתפרסם באתר זה ולכל נזק שעלול להיגרם. כל הזכויות על המידע באתר שייכות להסתדרות הרפואית בישראל. מדיניות פרטיות
        כתובתנו: ז'בוטינסקי 35 רמת גן, בניין התאומים 2 קומות 10-11, ת.ד. 3566, מיקוד 5213604. טלפון: 03-6100444, פקס: 03-5753303